By continuing to use this site, you consent to our use of cookies to personalize your experience and to analyze website traffic. Learn more in our Privacy Policy.

Accept
Privacy Policy

See results of a survey of people who tube feed conducted by Alcresta and the Oley Foundation #

#
RELiZORB (immobilized lipase) cartridge

RELiZORB is now FDA cleared for all ages

Hear real patient stories #

Hear real patient stories #

Meet Caleb, a child who tube feeds with RELiZORB

Graphic of a patient using RELiZORB feeding tube styled as a rocket backpack

Take fat absorption to the next level for proper tube-feeding nutrition

RELiZORB works with a wide variety of enteral nutrition types to help you get the most from every feed.

What could better fat absorption from your enteral nutrition mean for you?

Fat malabsorption occurs when your body can’t digest and absorb fats. Fats are vital to your health and for normal growth and development in children. If your body needs help breaking down fats from tube-feeding formula, your doctor may prescribe RELiZORB.

RELiZORB (immobilized lipase) cartridge and description of enfit compatibility

Improve nutrition and symptoms of tube-feeding intolerance with RELiZORB

  • Breaks down fats in enteral nutrition
  • Provides better fat absorption with every tube feed
  • Designed for a wide range of compatible enteral nutrition types*
  • Can be used with bolus and continuous feeds
  • For neonates and infants 6 months of age or younger, use up to 2 cartridges per day†
  • For infants greater than 6 months of age, pediatric and adult patients, use up to 6 cartridges per day†
Mary and partner holding RELiZORB
Hear stories from people who tube feed
#
RELiZORB (immobilized lipase) cartridge showing the immobilized lipase design
Get to know the RELiZORB cartridge
#
Image showing an illustration of the gastrointestinal tract
Discover the impacts of fat malabsorption
#
Person connecting a feeding tube to the RELiZORB cartridge
Learn how to set up RELiZORB
#
Video thumbnail of Caleb and his mother, Kayleigh, sharing their experience with using RELiZORB

Caleb’s story

Meet Caleb, a 6-year-old with short bowel syndrome (SBS), and his mother, Kayleigh, to hear about their experience managing his condition with RELiZORB

Hear more real stories

When it comes to tube feeding, did you know . . .

  • Over 430,000 people in the US tube feed at home
  • There are various medical conditions and procedures that might require someone to tube feed
  • Some people who tube feed can still eat small amounts of food by mouth
  • Tube feeding can be temporary or a lifelong solution to a nutritional need
  • People who tube feed can still maintain an active lifestyle
Caleb playing with his mom Kayleigh, part of the RELiZORB family story highlighting everyday moments with enteral feeding support

Caleb, a child who tube feeds with RELiZORB, and his mom, Kayleigh

Alcresta Therapeutics, Inc. and the Oley Foundation partnered to conduct a survey to better understand patients’ tube-feeding experiences.

According to the survey, most people who tube feed feel discomfort with their feeds. Fat malabsorption may be the cause of these symptoms.

Find out how addressing fat malabsorption can help.

* Please see the Compatibility Guide for more information.
† RELiZORB can be used as six 1-cartridge feeds or three 2-cartridge feeds for a maximum of 6 cartridges per day for those >6 months old. Use up to 2 single cartridges per day for those ≤6 months old. There are no requirements on the amount of time between using cartridges for either age group.

RELiZORB is indicated for use in pediatric (including neonates and infants) and adult patients to hydrolyze fats during enteral feeding.

Warnings
  • RELiZORB is for use with enteral tube feeding only.
See more
#

RELiZORB is indicated for use in pediatric (including neonates and infants) and adult patients to hydrolyze fats during enteral feeding.

Warnings
  • RELiZORB is for use with enteral tube feeding only.
  • RELiZORB should not be connected to any intravenous (IV) line, setup, or system.
  • Medications should not be administered through the RELiZORB cartridge. Do not add medications to the enteral nutrition or tubing before RELiZORB. The passage of medications through RELiZORB may adversely affect the medications or the ability of RELiZORB to hydrolyze fats.
  • Fibrosing Colonopathy - Fibrosing colonopathy is a rare, serious adverse reaction associated with high-dose use of pancreatic enzyme replacement therapy in the treatment of patients with cystic fibrosis. The underlying mechanism of fibrosing colonopathy remains unknown. Patients with fibrosing colonopathy should be closely monitored because some patients may be at risk of progressing to stricture formation. RELiZORB contains lipase enzyme that is not from a porcine source. The lipase is bound to the beads, and this lipase-bead complex (iLipase) is retained within the RELiZORB cartridge. Continue to follow your physician’s guidance and porcine pancreatic enzyme labeling regarding porcine pancreatic enzyme use when used in conjunction with RELiZORB.
Cautions and Precautions
  • Do not re-use RELiZORB. RELiZORB is a single-use product. Re-use may result in contamination of the product. If re-used, RELiZORB may not effectively hydrolyze fats.
  • Do not break, alter, or place excess pressure on any part of RELiZORB. Any compromise of the structural integrity of RELiZORB may lead to improper connection to enteral feeding supplies, leakage or risk of contamination.
  • Do not use RELiZORB after the date marked on the pouch.
  • Enteral nutrition administered through RELiZORB is for immediate consumption through an enteral feeding tube. RELiZORB should not be used to process enteral nutrition for later use. This has not been tested and may result in safety issues.
  • RELiZORB is designed for use with enteral feeding pump systems with low flow/no flow alarms and enteral syringes for manual bolus by syringe (push or gravity). A detailed listing of enteral nutrition, pumps, and enteral feeding supplies compatible with RELiZORB can be found at www.relizorb.com/compatibility.
  • Patients less than 1 year old may be particularly vulnerable to unplanned interruptions of feeding.
  • Do not use blenderized formulas with RELiZORB. A detailed listing of enteral nutrition compatible with RELiZORB can be found at www.relizorb.com/compatibility.
  • Powdered formulas should be mixed periodically during feedings.
  • Do not use excessive force on the plunger when using RELiZORB with bolus syringe feeding method.
  • Do not rush bolus feeds. Follow guidance from your healthcare professional on how long it should take you to complete your tube feeding. Ensure all inlet and outlet connectors on RELiZORB and enteral feeding supplies are clean and dry prior to making connections.
  • In order to ensure product performance, store RELiZORB in its pouch either refrigerated or at room temperature (2°C to 27°C; 36°F to 80°F).
  • RELiZORB is indicated for use with enteral feeding only; patients should follow physician’s guidance for pancreatic enzyme replacement therapy (PERT) use for meals and snacks. Patients and patient caregivers should follow physician’s guidance regarding the need for pancreatic enzyme replacement therapy (PERT) during enteral feeding.

Review full product information for RELiZORB in the Instructions for Use.